S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Why did Biden repeal Trump's Executive Order?! (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The End of America (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Buy THIS stock before Taiwan is attacked... (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Why did Biden repeal Trump's Executive Order?! (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The End of America (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Buy THIS stock before Taiwan is attacked... (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Why did Biden repeal Trump's Executive Order?! (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The End of America (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Buy THIS stock before Taiwan is attacked... (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Why did Biden repeal Trump's Executive Order?! (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The End of America (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Buy THIS stock before Taiwan is attacked... (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:NARI

Inari Medical - NARI Price Target & Analyst Ratings

$58.67
-4.50 (-7.12%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$58.26
$64.29
50-Day Range
$58.67
$77.69
52-Week Range
$50.50
$100.00
Volume
1.69 million shs
Average Volume
692,213 shs
Market Capitalization
$3.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$91.60

Inari Medical Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$91.60
56.13% Upside
High Prediction$105.00
Average Prediction$91.60
Low Prediction$75.00
TypeCurrent
1/28/22 to 1/28/23
1 Month Ago
12/29/21 to 12/29/22
3 Months Ago
10/30/21 to 10/30/22
1 Year Ago
1/28/21 to 1/28/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$91.60$92.80$91.78$128.25
Predicted Upside56.13% Upside29.70% Upside27.26% Upside42.04% Upside
Get Inari Medical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NARI and its competitors with MarketBeat's FREE daily newsletter.


NARI Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NARI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Inari Medical Stock vs. The Competition

TypeInari MedicalMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.64
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside56.13% Upside1,055.15% Upside9.94% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/6/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$95.00 ➝ $83.00+30.63%
12/20/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold$84.00 ➝ $75.00+7.81%
11/3/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $105.00+42.80%
10/17/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$100.00 ➝ $97.00+34.00%
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$88.00+20.83%
9/29/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$85.00+16.33%
9/16/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
William Plovanic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$92.00 ➝ $94.00+27.46%
6/21/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$100.00+64.18%
3/23/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy ➝ Buy
2/24/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$85.00 ➝ $95.00+25.00%
(Data available from 1/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NARI Price Target - Frequently Asked Questions

What is Inari Medical's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Inari Medical stock is Moderate Buy based on the current 1 hold rating and 9 buy ratings for NARI. The average twelve-month price prediction for Inari Medical is $91.60 with a high price target of $105.00 and a low price target of $75.00. Learn more on NARI's analyst rating history.

Do Wall Street analysts like Inari Medical more than its competitors?

Analysts like Inari Medical more than other Medical companies. The consensus rating for Inari Medical is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how NARI compares to other companies.

Does Inari Medical's stock price have much upside?

According to analysts, Inari Medical's stock has a predicted upside of 29.38% based on their 12-month price targets.

What analysts cover Inari Medical?

Inari Medical has been rated by Morgan Stanley, Truist Financial, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:NARI) was last updated on 1/28/2023 by MarketBeat.com Staff